MX428367B - Compuestos heterociclicos como moduladores del estimulador de genes de interferon (sting) - Google Patents
Compuestos heterociclicos como moduladores del estimulador de genes de interferon (sting)Info
- Publication number
- MX428367B MX428367B MX2022007178A MX2022007178A MX428367B MX 428367 B MX428367 B MX 428367B MX 2022007178 A MX2022007178 A MX 2022007178A MX 2022007178 A MX2022007178 A MX 2022007178A MX 428367 B MX428367 B MX 428367B
- Authority
- MX
- Mexico
- Prior art keywords
- sting
- stimulator
- modulators
- heterocyclic compounds
- interferon genes
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La presente invención se refiere a compuestos de la fórmula (I), así como a sales, estereoisómeros, tautómeros o N-óxidos de dichos compuestos que son útiles como moduladores de STING (estimulador de genes de interferón). La presente invención se refiere además a los compuestos de la fórmula (I) para su uso como un medicamento y a una composición farmacéutica que comprende dichos compuestos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19460064 | 2019-12-11 | ||
| PCT/EP2020/085840 WO2021116451A1 (en) | 2019-12-11 | 2020-12-11 | Heterocyclic compounds as modulators of stimulator of interferon genes (sting) |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2022007178A MX2022007178A (es) | 2022-07-13 |
| MX428367B true MX428367B (es) | 2025-11-13 |
Family
ID=69137701
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022007178A MX428367B (es) | 2019-12-11 | 2020-12-11 | Compuestos heterociclicos como moduladores del estimulador de genes de interferon (sting) |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US12655124B2 (es) |
| EP (1) | EP4073063A1 (es) |
| JP (1) | JP7426486B2 (es) |
| KR (2) | KR20260022465A (es) |
| CN (1) | CN114787147A (es) |
| AU (2) | AU2020400010B2 (es) |
| BR (1) | BR112022010611A2 (es) |
| IL (1) | IL293527B2 (es) |
| MX (1) | MX428367B (es) |
| WO (1) | WO2021116451A1 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3807264A1 (en) | 2018-06-12 | 2021-04-21 | Ryvu Therapeutics S.A. | Modulators of stimulator of interferon genes (sting) |
| MX2021015188A (es) * | 2019-06-12 | 2022-01-18 | Ryvu Therapeutics S A | Moduladores de nueva generacion del estimulador de genes de interferon (sting). |
| CN113950473B (zh) * | 2019-06-12 | 2025-07-22 | 雷沃医疗有限公司 | 干扰素基因刺激物(sting)的下一代调节剂 |
| CN114787148A (zh) | 2019-12-11 | 2022-07-22 | 雷沃医疗有限公司 | 官能化杂环化合物作为干扰素基因刺激物(sting)的调节剂 |
| KR20260022465A (ko) | 2019-12-11 | 2026-02-19 | 리부 세라퓨틱스 에스.에이. | 인터페론 유전자 자극제(sting)의 조절제인 헤테로사이클릭 화합물 |
| WO2023158862A2 (en) * | 2022-02-21 | 2023-08-24 | Geode Therapeutics Inc. | Stimulator of interferon genes (sting) modulators, and compositions and methods thereof |
| GB202304385D0 (en) | 2023-03-24 | 2023-05-10 | Prostate Cancer Res | Combinatorial IL-15 therapy |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3410851A (en) | 1963-09-03 | 1968-11-12 | Miles Lab | Derivatives of flavone |
| GB0225833D0 (en) | 2002-11-06 | 2002-12-11 | Univ Leeds | Nucleic acid ligands and uses therefor |
| TW200803855A (en) * | 2006-02-24 | 2008-01-16 | Kalypsys Inc | Quinolones useful as inducible nitric oxide synthase inhibitors |
| AU2007247385B2 (en) * | 2006-05-10 | 2011-07-14 | Novartis Ag | Bicyclic derivatives as CETP inhibitors |
| EP2365749A4 (en) * | 2008-11-13 | 2012-05-30 | Merck Sharp & Dohme | Quinolone NEURO PEPTIDE-S-Receptor Antagonists |
| JP6209605B2 (ja) | 2012-06-28 | 2017-10-04 | ノバルティス アーゲー | ピロリジン誘導体、および補体経路調節因子としてのその使用 |
| GB2563642A (en) * | 2017-06-22 | 2018-12-26 | Curadev Pharma Ltd | Small molecule modulators of human STING |
| CN111132972B (zh) | 2017-06-22 | 2024-07-12 | 克拉德夫制药有限公司 | 人sting的小分子调节剂 |
| US20200138827A1 (en) | 2017-06-22 | 2020-05-07 | Curadev Pharma Limited | Small molecule modulators of human sting |
| WO2019023635A1 (en) * | 2017-07-27 | 2019-01-31 | Stingray Therapeutics, Inc. | SUBSTITUTED 3 H-IMIDAZO (4,5-C) PYRIDINE AND 1H-PYRROLO (2,3-C) PYRIDINE SERIES OF A NOVEL ECTONUCLEOTIDE PYROPHOSPHATASE / PHOSPHODIESTERASE-1 (ENPP1) AND STIMULATOR FOR A GENE MODULATOR INTERFERON (STING) AS IMMUNOTHERAPEUTIC AGENTS AGAINST CANCER |
| BR112020009592A2 (pt) | 2017-11-20 | 2020-11-03 | Silicon Swat, Inc. | derivados de ácido oxoacridinil acético e métodos de uso |
| EP3768266A4 (en) | 2018-03-20 | 2021-12-22 | Merck Sharp & Dohme Corp. | OXO-TETRAHYDRO-ISOCHINOLINE-CARBOXYLIC ACIDS AS STING INHIBITORS |
| EP3807264A1 (en) * | 2018-06-12 | 2021-04-21 | Ryvu Therapeutics S.A. | Modulators of stimulator of interferon genes (sting) |
| JP7475370B2 (ja) | 2019-05-10 | 2024-04-26 | 河南知微生物医薬有限公司 | ブルトン型チロシンキナーゼ阻害剤としての置換されている1-アミノ-1h-イミダゾール-5-カルボキサミド |
| MX2021015188A (es) * | 2019-06-12 | 2022-01-18 | Ryvu Therapeutics S A | Moduladores de nueva generacion del estimulador de genes de interferon (sting). |
| CN114787148A (zh) | 2019-12-11 | 2022-07-22 | 雷沃医疗有限公司 | 官能化杂环化合物作为干扰素基因刺激物(sting)的调节剂 |
| KR20260022465A (ko) | 2019-12-11 | 2026-02-19 | 리부 세라퓨틱스 에스.에이. | 인터페론 유전자 자극제(sting)의 조절제인 헤테로사이클릭 화합물 |
-
2020
- 2020-12-11 KR KR1020267001518A patent/KR20260022465A/ko active Pending
- 2020-12-11 CN CN202080085968.2A patent/CN114787147A/zh active Pending
- 2020-12-11 MX MX2022007178A patent/MX428367B/es unknown
- 2020-12-11 WO PCT/EP2020/085840 patent/WO2021116451A1/en not_active Ceased
- 2020-12-11 BR BR112022010611A patent/BR112022010611A2/pt unknown
- 2020-12-11 AU AU2020400010A patent/AU2020400010B2/en active Active
- 2020-12-11 US US17/783,947 patent/US12655124B2/en active Active
- 2020-12-11 EP EP20823808.9A patent/EP4073063A1/en active Pending
- 2020-12-11 JP JP2022535700A patent/JP7426486B2/ja active Active
- 2020-12-11 IL IL293527A patent/IL293527B2/en unknown
- 2020-12-11 KR KR1020227023490A patent/KR102915463B1/ko active Active
-
2024
- 2024-01-16 AU AU2024200264A patent/AU2024200264B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2024200264B2 (en) | 2025-09-11 |
| AU2020400010B2 (en) | 2024-01-25 |
| JP7426486B2 (ja) | 2024-02-01 |
| KR20220113473A (ko) | 2022-08-12 |
| IL293527A (en) | 2022-08-01 |
| MX2022007178A (es) | 2022-07-13 |
| US20230076506A1 (en) | 2023-03-09 |
| AU2024200264A1 (en) | 2024-02-01 |
| CN114787147A (zh) | 2022-07-22 |
| EP4073063A1 (en) | 2022-10-19 |
| KR102915463B1 (ko) | 2026-01-19 |
| US12655124B2 (en) | 2026-06-16 |
| CA3159968A1 (en) | 2021-06-17 |
| AU2020400010A1 (en) | 2022-05-26 |
| WO2021116451A1 (en) | 2021-06-17 |
| IL293527B2 (en) | 2026-04-01 |
| IL293527B1 (en) | 2025-12-01 |
| JP2023505878A (ja) | 2023-02-13 |
| KR20260022465A (ko) | 2026-02-19 |
| BR112022010611A2 (pt) | 2022-09-06 |